Clinical Trial Update: Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of nilotinib in mild-to-moderate Alzheimer's disease has completed. The update summarizes safety, biomarker data, and clinical outcomes from the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Georgetown University | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED